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The vascular complications of diabetes mellitus impose a huge burden on the management of this disease. The higher incidence of
cardiovascular complications and the unfavorable prognosis among diabetic individuals who develop such complications have
been correlated to the hyperglycemia-induced oxidative stress and associated endothelial dysfunction. Although antioxidants
may be considered as eﬀective therapeutic agents to relieve oxidative stress and protect the endothelium, recent clinical trials
involving these agents have shown limited therapeutic eﬃcacy in this regard. In the recent past experimental evidence suggests
that endoplasmic reticulum (ER) stress in the endothelial cells might be an important contributor to diabetes-related vascular
complications. The current paper contemplates the possibility of the involvement of ER stress in endothelial dysfunction and
diabetes-associated vascular complications.
1.Introduction
Diabetes mellitus (DM) is a growing metabolic disease that
continues to be a leading health problem worldwide. The
World Health Organization (WHO) has estimated that
there are currently 346 million people aﬀected by diabetes
worldwideandanticipatesthatdiabetes-relateddeathswould
doubleby2030[1].Theseﬁgureshighlighttheimportanceof
continued research and the need for novel methods to both
prevent and treat this pandemic.
The adverse long-term eﬀects of DM involve many organ
systems and are associated with a complex pathology involv-
ing a large number of secondary cellular and subcellular
changes. While diabetes management has largely focused on
control of hyperglycemia, the rising burden of this disease
is mainly correlated to its vascular complications [2, 3].
This is reﬂected by a 4-fold increase in the incidence of
coronary artery disease, a 10-fold increase in peripheral
vascular disease, and a 3- to 4-fold higher mortality rate
with as much as 75% of diabetics ultimately dying from
vascular disease [4]. Type II diabetes diﬀers principally from
type I diabetes in that it is accompanied by a period of
hyperinsulinemia and is characterized by late as opposed
to early onset of hyperglycemia. In type I DM, vascular
involvement (through endothelial dysfunction) occurs as a
result of metabolic insult/hyperglycemia, while in type II
DM, endothelial dysfunction plays a more direct role, and
is aggravated by, rather than caused by, hyperglycemia [5].
The high glucose-induced “oxidative stress”a n d“ endo-
plasmic reticulum (ER) stress” (which might be dependent on
oxidative stress) of the endothelium may play major roles
in the initiation and progression of cardiovascular clinical
manifestations in diabetes. The following sections of this
paper will provide evidence on the molecular mechanisms of
endothelial dysfunction in diabetes with special reference to
the role of hyperglycemia/oxidative stress-induced ER stress
in the endothelium.
2.Endothelial Dysfunctionand Vascular
Complications inDiabetes
Endothelial cells line the internal lumen of all the vasculature
and serve as an interface between circulating blood and
vascular smooth muscle cells (VSMCs) [6]. Apart from
being the key participant during the process of angiogen-
esis, these dynamic structures can actively regulate basal
vascular tone and vascular reactivity in physiological and
pathological conditions. They respond to mechanical forces2 Experimental Diabetes Research
and neurohumoral mediators by releasing a variety of relax-
ing and contracting factors such as nitric oxide (NO) and
prostacyclin [7]. The balance between the vasodilatation and
vasoconstriction is maintained by the endothelium, and the
disruption of this balance leads to endothelial dysfunction
andcausesdamagetothearterialwall[8,9].Endothelialcells
arealsoresponsibleforthemaintenanceofbloodﬂuidityand
restoration of vessel wall integrity (when injured) to avoid
bleeding [7]. Endothelial cell-derived factors also are critical
mediators of VSMC growth and inﬂammation [10].
Loss of function/regulation of function of the endothe-
lium (endothelial dysfunction) in a basal state or after activa-
tionmaybeacriticalandinitiatingfactorinthedevelopment
of diabetic micro- and macrovascular disease [2, 11]. Blood
glucose levels continue to be the principal link between
diabetes and vascular disease. In diabetics and normal sub-
jects, results of glucose tolerance tests have shown rapid loss
of brachial artery endothelium-dependent vasodilatation—
with fast recovery in normal subjects and a slower recovery
in diabetics [12]. This emphasizes that even in nondiabetics,
postprandial exposure to elevated blood glucose can disturb
the endothelium-dependent regulation of blood ﬂow [13].
The microvascular complications in diabetes include
retinopathy, nephropathy, and neuropathy, while macrovas-
cular complications are manifested in ischemic heart disease,
stroke, and peripheral vascular disease [3, 14]. “Aberrant”
angiogenesis (one of the main functions of endothelial cells)
is one of the main reasons for these vascular complications
associated with diabetes [15]. However, it must be noted
that diabetic vascular complications associated with aber-
rant/altered angiogenesis may either be caused by exces-
sive angiogenesis (retinopathy, nephropathy) or deﬁcient
angiogenesis (impaired wound healing, impaired collateral
vessel formation, neuropathy, embryonic vasculopathy, and
transplant rejection) [15].
Several diabetes-related studies have identiﬁed an array
of molecular entities and pathways that inﬂuence endothelial
function and reported how altered endothelial function
and changes in endothelial cell-derived factors can lead to
vascular complications in a hyperglycemic setting. There is,
however, no distinct pathway that causes vascular disease in
diabetes, due to the simple fact that the dysregulation of
glucose homeostasis (the deﬁning feature of diabetes) can
in itself occur either in the absence or presence of insulin,
not to mention other frequent comorbid diseases such as
hypertension and obesity. Therefore, the cellular processes
underlying endothelial dysfunction are not yet clearly under-
stood, and multiple mechanisms are probably involved. A
better understanding of endothelial dysfunction in a diabetic
setting would aid in the search for novel approaches in the
prevention and treatment of diabetes vascular disease.
3. Etiology of Endothelial
DysfunctioninDiabetes
Type II diabetes is characterized by three main metabolic
disturbances (triggers): (1) hyperlipidemia,( 2 )e a r l yhyperin-
sulinemia, and (3) hyperinsulinemia followed by pancreatic
β-cell failure leading to hyperglycemia [16]. Each of these
metabolic disturbances acts as “triggers” eventually causing
endothelial dysfunction through the inﬂuence of diﬀerent
“mediator” molecules [17–19]. In a clinical setting it might
be diﬃcult to validate how much damage is caused in
terms of endothelial dysfunction by each of these metabolic
changes. However, several lines of evidence point to the fact
that “oxidative stress” caused by these metabolic changes
plays a key role in endothelial dysfunction [7, 20].
Among these metabolic changes hyperglycemia has
been recognized as the primary cause in the pathogene-
sis of diabetic vascular disease and other complications.
Hyperglycemia-induced increase in glucose oxidation and
mitochondrial generation of superoxide anion (O2
•−)i n
turn leads to DNA damage and activation of poly (ADP
ribose) polymerase (PARP) as a reparative enzyme [16, 21].
PARP-induced ADP ribosylation of glyceraldehyde phos-
phate dehydrogenase (GAPDH) then diverts glucose from
its glycolytic path into alternative biochemical pathways
leading to increase in advanced glycation end products
(AGEs), hexosamine and polyol ﬂux, and activation of
classical isoforms of protein kinase C, that are considered the
mediators of hyperglycemia-induced cellular injury [16, 21–
25]. Though there are several diﬀerent pathways involved in
hyperglycemia-mediated endothelial dysfunction, evidence
suggests that all these diﬀerent pathways/mechanisms that
are induced by hyperglycemia lead to considerable genera-
tion of reactive oxygen species (ROS), which is responsible
for the oxidative stress; however, metabolism of glucose
may not be a requirement for the generation of ROS [26].
Oxidative stress or the increase in the levels of ROS in the
biological system is known to occur due to increased activity
of the ROS-generating systems and/or decreased antioxidant
defense mechanisms [27] .T h ee x c e s s i v eR O Ss of o r m e dc a n
then aggravate cellular injury by promoting activation of
the biochemical pathways (autooxidation of glucose, AGE
formation, activation of the polyol pathway, and stimulation
of the eicosanoid metabolism) that initiate ROS generation
in the ﬁrst place as a response to hyperglycemia, thus
completing a vicious cycle [28]( Figure 1).
The excessive ROS generation is known to impair
endothelial nitric oxide synthase (eNOS) activity and
NO production thereby aﬀecting endothelium-dependent
vasodilation [23]. Hyperglycemia-induced oxidative stress
has also been associated with increased endothelial cell
apoptosis in vitro and in vivo [29]. Several antioxi-
dant therapies were found to improve or normalize the
endothelium-dependent responses in diﬀerent models of
diabetes and hyperglycemia as well as signiﬁcantly decrease
the hyperglycemia-induced apoptosis [28–30]. Both exper-
imental and clinical evidence thus suggest compromised
endothelial function in diabetic conditions and identiﬁed
hyperglycemia and/or hyperglycemia-mediated oxidative
stress as the major causative factor for the cardiovascular
pathological conditions that follow [7, 27, 28].
4. Molecular Basis of Endothelial Dysfunction
inDiabetes—CurrentUnderstanding
Endothelial cells have multiple physiological functions, and
therefore alterations in endothelial cell function may aﬀectExperimental Diabetes Research 3
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Figure 1: Hyperglycemia-induced oxidative stress and endothelial dysfunction (possible role of ER stress). High glucose levels in circulation
can divert glucose into alternative biochemical pathways leading to the increase in advanced glycation end products (AGEs), glucose
autooxidation, hexosamine and polyol ﬂux, and activation of classical isoforms of protein kinase C, that are considered to be the mediators
of hyperglycemia-induced cellular injury. Many diﬀerent pathways involved in hyperglycemia-mediated endothelial dysfunction induced by
hyperglycemia lead to considerable generation of reactive oxygen species (ROS), which is responsible for the oxidative stress. The excessive
ROS so formed can then aggravate cellular injury by promoting activation of the biochemical pathways (red dotted arrows) that initiate
ROS generation in the ﬁrst place as a response to hyperglycemia, thus completing a vicious cycle. Superoxide anion (O2
•−) can also react
with NO to yield peroxynitrite which is also known to be a mediator of endothelial dysfunction. It is still unclear whether the ER stress
response can be initiated as a direct response to the increasing load on protein synthesis and maturation due to hyperglycemia or due to the
hyperglycemia-associated oxidative stress. The possibility that ER stress response also can lead to excessive ROS formation cannot be ruled
out.4 Experimental Diabetes Research
one or more of these systems, either simultaneously or
at distinct time periods [7]. Thus, either an increase or
a decrease in any of the endothelial cell-related chemical
messengers and/or alterations in any of the endothelial cell-
related functions may contribute to the development of
endothelial dysfunction [7].
In type I diabetic patients, reports ofpoor vasodilatation,
increased blood levels of von Willebrand factor (vWF),
thrombomodulin, selectins, type IV collagen, and so forth
are indicators of endothelial cell dysfunction [7]. These
pathological changes can then induce alterations in the
vasculature and is known to support the progression of the
disease condition. endothelin-1 (ET-1), a potent vasocon-
strictorandmitogenproducedbyendothelialcellsthatacton
VSMCs, is signiﬁcantly increased in hyperglycemic/diabetic
conditionsandplaysacriticalroleinthedevelopmentofvas-
cular diseases [31, 32]. Additionally, increased activation of
protein kinase C (PKC), angiotensin II (ANG-II), increased
levels of advanced glycation end products (AGEs), increased
plasminogen activity inhibitor-1 (PAI-1), and so forth have
been related to endothelial dysfunction in diabetes.
Increased inﬂammatory activation has also been linked
to diabetic vascular complications [5]. Human aortic
endothelial cells (HAECs) exposed to transient hyper-
glycemia have exhibited epigenetic changes in the p65 sub-
unit of NFκB gene, with increased expression of monocyte
chemoattractant protein -1 (MCP-1), vascular cell adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), interleukin-6 (IL-6), and inducible nitric oxide
synthase (iNOS) [33, 34]. Also, a rise in the soluble forms of
VCAM-1 and ICAM-1 (leukocyte adhesion molecules) has
been observed in diabetic patients and is associated with an
increased cardiovascular disease risk [35, 36]. Furthermore,
there is a moderate elevation in plasma C-reactive protein
levelsindiabetic andatheroscleroticpatients,whichcouldbe
amanifestationoflow-gradechronicinﬂammationofvessels
[37–40].
In vitro and in vivo studies demonstrated that the ac-
tivity of eNOS and generation of nitric oxide (NO) are sig-
nificantly reduced in endothelial cells exposed to a hyper-
glycemic environment [7, 9, 23, 41]. It has been demon-
strated that mouse microvascular endothelial cells (MMECs)
develop oxidative stress after exposure to high glucose
[42]. NADPH oxidase is activated by high glucose and
acts as the primary source of ROS (speciﬁcally O2
•−),
and this activation promotes eNOS uncoupling and higher
production of H2O2 and superoxide. The excess O2
•− may
also quench NO thereby reducing its bioavailability leading
to reduced endothelium-dependent vasodilatation [43–45].
Reports have also suggested that hyperglycemia-induced
O2
•− production is accompanied by an increase in NO
formation as a result of the activation of inducible NOS
(iNOS) [21]. The O2
•− a n dN Or e a c tt oy i e l dp e r o x y n i t r i t e
(ONOO
−), a strong oxidant, which in turn is known to
contribute signiﬁcantly to endothelial dysfunction [46–48]
(Figure 1). Peroxynitrite oxidizes tetrahydrobiopterin (BH4),
an essential cofactor in the regulation of eNOS and iNOS
levels in endothelial cells, and its levels are aﬀected by acute
rises in plasma glucose [21, 42, 49–51]. BH4 is known to
stabilize the dimeric forms of NOS, which would otherwise
remain as a monomer [21, 52–54]. BH4 is therefore of prime
importance in the maintenance of endothelial function, and
it has been shown to be aﬀected early in both humans and
mice in type II diabetes [44, 55].
Recent evidence suggests that hyperglycemia-induced
endothelial cell dysfunction may occur secondary to
increased oxidant stress and a concomitant increase in ER
stress [56, 57]. Although oxidative stress can induce ER
stress, it is still unclear whether these cellular responses are
causally linked or two independent eﬀects of high glucose
exposure. The following sections of this paper dwell upon
the possible role of ER stress in endothelial dysfunction in a
diabetic milieu.
5. ER Stress: GeneralOverview
Apart from playing a key role as a central eukaryotic
membranous organelle, formed in continuity with the outer
membrane of the nuclear envelope and responsible for syn-
thesis, folding, and maturation of membrane and secreted
proteins, lipid biosynthesis, and calcium storage, the endo-
plasmic reticulum (ER)actsastheprime qualitycontrolcen-
tre and signal transducing entity that can sense and respond
to changes in cellular homeostasis [58, 59]. The intra-ER
milieu provides a Ca2+- rich, unique oxidizing environment,
which is critical for the formation of disulphide bonds and
for protein folding and assembly into its precise native
conformations prior to transport to the Golgi compartment
[58,59].Inaddition,accuracyinproteinfoldingisalsomon-
itored by the many Ca2+-dependent molecular chaperones,
which stabilize the protein folding intermediates [60].
The entry of unfolded polypeptide chains, as they are
synthesized, into the ER remains largely variable, changing
rapidly in response to the diﬀerent ongoing cellular process,
the environment, and the physiologic state of the cell [61,
62]. As such the ER must be highly receptive to these changes
and critically respond in the best interest of maintaining
cell integrity and normal function. The normal physiological
state of the ER is challenged when the inﬂux of the nascent
unfolded polypeptides exceeds the processing capacity of the
ER (ER stress) [63]. In such a scenario the cell responds
to the increasing presence of unfolded proteins within the
ER through the activation of an intricate set of integrated
signaling pathways that relay information from the ER to
the cytosol and the nucleus, aiming to restore normal ER
and cellular functions [63–65]. In fact, a cell’s life and
death decisions are made by these pathways depending on
whether the ER stress is resolved or not. These pathways,
known as the unfolded protein response (UPR) or ER stress
response are thus critical for normal cellular homeostasis,
development of the organism, and are also known to play
major roles in the pathogenesis of many diseases such as
diabetes, obesity, inﬂammation, cardiovascular disorders,
viral infections, neurodegeneration, and cancer [64, 66–71].
The UPR engages to alleviate ER stress by (1) tran-
scriptional induction of UPR genes (e.g.: chaperones to
enhance folding capacity), (2) translational attenuation of
global protein synthesis (to reduce the ER workload andExperimental Diabetes Research 5
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Figure 2: Signal transduction events associated with ER stress. The accumulation of misfolded proteins and disruption of Ca2+ homeostasis in
the ER disrupt ER function leading to ER stress. The unfolded protein response (UPR) is initiated as a response to this stress, where GRP78,
PERK, IRE1, and ATF6 play a central role. However, there might be more unknown mediators of ER stress. The cell initially tries to resolve
the ER stress and restore normal cell function by halting protein synthesis and activation of several ER Stress Response (ERSR) adaptation
genes, which include chaperones and proteins of the ER-associated degradation (ERAD) system. However, prolonged ER stress leads to the
activation of the “alarm response”, leading to cell damage, dysfunction, and ﬁnally apoptosis.
thus decreases further production of misfolded proteins),
and ﬁnally (3) ER-associated degradation (ERAD, to remove
and clear unfolded proteins from the ER lumen) [65]. This
tripartite mode of response ensures that, in the event that the
stress responses are insuﬃcient to restore the ER environ-
ment (ER stress remains unresolved with an environment
suboptimal for proper protein folding), the cell is destined
for programmed cell death/apoptosis [66, 72–74]. At the
molecular level the three main proximal transducers of
ER stress are: (1) protein-kinase-like ER Kinase (PERK),
(2) inositol requiring protein-1 (IRE1), and (3) activating
transcription factor-6 (ATF6) [65]( Figure 2).
PERK, an ER transmembrane, dimerizes and under-
goes trans-autophosphorylation upon ER stress. The active
phosphorylated from of PERK phosphorylates the α-subunit
of eukaryotic translation initiation factor 2-alpha (eIF2α),
leading to reduced recognition of AUG initiation codons,
translational attenuation, and thus reduction of unfolded
proteins in the ER [53, 60, 63]. To ensure that the
translational attenuation is reversed once the ER stress is
relieved, the translation of mRNA encoding genes such
as activating transcription factor-4 (ATF4), which have a
lower requirement of eIF2, is enhanced [61]. ATF4 then
induces growth arrest and DNA damage-inducible protein-
34 (GADD34), which in turn recruits protein phosphatase-1
(PP1) to dephosphorylate the PERK-phosphorylated eIF2α
thus reversing translational attenuation [61, 75]( Figure 3).
IRE1,aubiquitouslyexpressedERtransmembraneglyco-
protein, is unique in the fact that it contains both kinase and
endoribonuclease activities in the cytoplasmic domain [76].
Oligomerization and trans-autophosphorylation of IRE1
in response to ER stress activates its endoribonucleolytic
activity, which then speciﬁcally excises an intron of the X-
box binding protein-1 (XBP1) mRNA to generate a mature
XBP1 mRNA [77]. This XBP1 mRNA with a new open
reading frame encodes for a 376aa protein and a C-terminal6 Experimental Diabetes Research
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Figure 3: Signaling by PERK, IRE1, and ATF6. In an unstressed condition, GRP78, the primary sensor of ER stress binds to transmembrane
ER proteins, PERK, IRE1, and ATF6, preventing their activation. The accumulation of unfolded proteins leads to dissociation of GRP78
from PERK, IRE1, and ATF6. GRP78, however, binds to the unfolded protein. GRP78 dissociation leads to PERK and IRE1 oligomerization
and trans-autophosphorylation of their cytosolic domains. The active phosphorylated PERK (p-PERK, active) in turn phosphorylates
eIF2α (p-eIF2α, inactive), leading to attenuation of global protein synthesis. Under these conditions, selected mRNAs, such as ATF4, are
translated, which induces the expression of genes involved in restoring ER homeostasis. ATF4 can activate GADD34, which recruits a
phosphatasetodephosphorylatep-PERKandreversetranslationalattenuation.ER-residentp58IPKsisaninhibitorofPERK.Phosphorylation
of IRE1 (p-IRE1) activates its endoribonucleolytic activity, which then excises an intron of the XBP1 mRNA to generate a mature XBP1
mRNA, which then encodes for the active protein, XBP1. The XBP1 protein then translocates into the nucleus and supports the ER stress
response. Interaction of p-IRE1 with TRAF2 can elicit the activation of the JNK pathway and caspases leading to apoptosis. GRP78 release
from the dimeric ATF6 leads to the translocation of its monomeric form to the Golgi, where it undergoes proteolytic processing by the
proteases (S1P and S2P). The cleaved ATF6 then translocates to the nucleus where it activates the ERSR genes and chaperones. Alternatively,
CHOP/GADD153 can be activated by ATF4, ATF6, or XBP1, which promotes apoptosis by decreasing the levels of antiapoptotic Bcl-2 in the
cell. The dotted arrows denote translocation. XBP1 (a) denotes the mature XBP1 mRNA, while XBP1p denotes the protein product of XBP1
(a). The “+” sign signiﬁes activation.
transcriptional activation domain and translocates to the
n u c l e u sw h i c ht h e ni n d u c en u m e r o u sE Rs t r e s sr e s p o n s e
genes [61, 76–78]( Figure 3).
ATF6 (670aa), though an ER transmembrane like PERK
and IRE1, exists as a dimer (α and β) in the absence of
ER stress [61–63, 65]. ER stress facilitates the translocation
of the monomeric forms of ATF6 (∼90kDa) to the Golgi
lumen where they are cleaved by the S1P and S2P proteases,
yielding N-terminal cytosolic (∼400aa, 50kDa) fragments,
which translocate to the nucleus and drive the activation of
many ER stress response genes [61–63, 65]( Figure 3).
Although, PERK, IRE1, and ATF6 eﬃciently relay in-
formation to the nucleus regarding the accumulation of mis-
folded proteins in ER stress, the master regulator and sensor
or ER stress seems to be the glucose regulated protein-78
(GRP78)[65]. GRP78 serves as a negative regulator of PERK,
IRE1, and ATF6 by interacting with the luminal domains of
these proteins in the absence of stress. The accumulation of
unfolded proteins in the ER leads to the release of GRP78
(which binds to the unfolded proteins) from the transducers
followed by subsequent activation of the UPR [61, 66].
While GRP78 dissociation form PERK and IRE1 permits
their dimerization and activation, the release of GRP78 from
the dimeric ATF6 permits its translocation to the golgi
lumen where it is subjected to intramembrane proteolysis as
mentioned earlier [79, 80]( Figure 3).
In conditions where the stress causing the UPR cannot
be resolved, leading to the continuous accumulation of
unfolded proteins in the ER, the aim of the UPR switches
g e a r sf r o map r o s u r v i v a lm o d et ot h a to fap r o a p o p -
totic mode [65]. Although well-known pathways such as
the NFκB signaling, the JNK signaling pathway, and the
p38MAPK pathway are known to play important roles in
IRE1-mediated initiation of apoptosis, the contribution ofExperimental Diabetes Research 7
each of these pathways or crosstalk between them requires
further experimental clariﬁcation [59]. The proapoptotic
CHOP/GADD153 is upregulated downstream of ATF4,
which in turn downregulates the antiapoptotic Bcl-2, favor-
ing mitochondrial cytochrome c release, caspase activation,
and eventually apoptosis [81].
6.ERStress andEndothelial Dysfunctionin
Diabetes—PossibleLinks
ER stress and the UPR play important roles in the pan-
creatic islet cell survival and function [82]. Accumulation
of misfolded mutant insulin (in type I diabetes) in the ER
of pancreatic β-cells causes chronic ER stress [83]. PERK
overactivation in such cases and lack of p58IPK (a PERK
inhibitor), which is necessary in derepression of translation
attenuation caused by PERK, are known to cause pancreatic
β-cell apoptosis, leading to type I diabetes [84, 85]. Addi-
tionally, defective islet proliferation and increased ER stress-
induced apoptosis were observed in PERK-deﬁcient mice
which are known to develop severe hyperglycemia soon after
birth [86]. While mice on a high fat diet with heterozygous-
targeted mutation of the PERK substrate, eIF2α, exhibit
glucose intolerance, mice with homozygous mutation of the
eIF2α phosphorylation site (Ser51Ala) die prenatally with
diabetes and pancreatic β-cell deﬁciency [70, 87]. Obesity,
one of the leading cause of type II diabetes, evokes ER stress
in the peripheral tissues by activation of IRE1-induced JNK-
dependentserinephosphorylationofIRS1,leadingtoinsulin
resistance [88]. While IRE1α−/− and XBP−/− knockout
mice are not viable, XBP+/− mice are known to exhibit
insulin resistance and type II diabetes [88–90].
The above-mentioned evidence, though suggestive of the
possible role of ER stress in the development of diabetes,
does not shed light on the role of ER stress and UPR in
the vascular complications that follow hyperglycemia. The
ER, exquisitely sensitive to glucose availability, depends on
the blood glucose levels for the energy supply required for
the protein folding process [91]. Endothelial cells, always
exposed to elevations and reductions of blood nutrients,
are very dynamic, metabolically active cells, with a high
volume of protein synthesis, which predispose them to ER
stress [92]. Endothelial cells in particular cannot tolerate
the continued high glucose exposure, and thus ER stress is
initiated in a diabetic milieu [93]. However, it is yet unclear
whether endothelial dysfunction in response to high glucose
levels occurs secondary to increased oxidative stress and a
concomitant increase in ER stress or vice versa.
6.1. High Glucose-Induced Oxidative Stress and ER Stress—
Double Edged Sword—Which Side Is Sharper? Several studies
suggest that hyperglycemia-induced oxidative stress con-
tributes to signiﬁcant endothelial dysfunction and vas-
cular complications in diabetes (brieﬂy reviewed under
the subheadings Etiology of Endothelial Dysfunction in
Diabetes and Molecular Basis of Endothelial Dysfunction in
Diabetes—Current Understanding, in this paper). Although
there are some studies suggesting that glucose-induced ER
stress is independent of oxidative stress in endothelial cells
[94], a large body of evidence suggest that oxidative stress
induces ER stress and vice versa [91, 95]. Since the ER
maintains an oxidative environment which favours protein
folding and maturation, increase in the protein synthesis
and protein folding load in response to hyperglycemia can
lead to the accumulation of ROS [96]. In order to limit
the accumulation of ROS, the PERK pathway is known
to activate an antioxidant program (including the GSH)
though ATF4 and NRF2 activation [96]. Hyperglycemia-
mediated changes in the PERK pathway may thus contribute
to ROS accumulation due to impaired antioxidant response.
Recently, paraoxonase-2 (PON2), an ER-resident enzyme,
is known to reduce ROS generation in the ER, thus
moderating ROS-activated ER stress and reducing apoptosis
of endothelial cells [97, 98].
As mentioned earlier, UPR ﬁrst aims to restore cellular
homeostasis by controlling the accumulation of misfolded
proteins in the ER. In particular, GRP78, the ER stress-
induced chaperone, is sensitive to glucose concentration and
shown to be induced in endothelial cells [99]. ER stress
inducers such as thapsigargin and tunicamycin are known to
induce GRP78 expression in endothelial cells [92]. GRP78
induction may also protect human endothelial cells from
oxidative stress-induced cellular damage [100].
NADPH oxidase, the prime source of ROS in endothelial
cells is activated in presence of high glucose with a concomi-
tant decrease in the generation of NO [26, 42–44, 101, 102].
Nox1/Nox2 activation (produce superoxide anions) upon
high glucose exposure leads to the formation of detrimental
levels of ROS which can salvage NO to form ONOO− and
cause eNOS uncoupling [103]. On the other hand, Nox4
(protective and produces H2O2 constitutively) activation
leads to controlled ROS production which is known to play
a signiﬁcant role on endothelial cell signaling and vasodilata-
tion [103]. NADPH oxidase (Nox1/Nox2) activation might
link ER stress and oxidative stress to the high glucose-
induced apoptosis of endothelial cells [104]. Nox2 activa-
tion and oxidative stress further amplify CHOP/GADD153
induction, which in turn promotes apoptosis. Reports sug-
gest that CHOP induction and apoptosis as a response to ER
stress is reduced in Nox2-deﬁcient mice thereby preventing
renal dysfunction [104].Thismightbetrueforhighglucose-
exposed endothelial cells where Nox2 activation has shown
to induce apoptosis [105] which might be possibly through
the activation of CHOP-mediated ER stress response.
High glucose-induced ROS generation disrupt Ca2+
homeostasis leading to leakage of Ca2+ from the ER lumen
[95, 106]. As mentioned earlier, intra-ER Ca2+ levels are
critical, since many ER chaperones depend on Ca2+ for
their activity [60]. A decrease in intra-ER Ca2+ can thus
impair the UPR leading to a situation where the ER stress
is not resolved when the cell must ﬁnally decide to undergo
apoptosis [105]. In endothelial cells exposed to high glucose,
disrupted Ca2+ homeostasis, due to ROS generation, can
thus evoke an apoptotic response which may be induced by
ER stress response mediators [107]. Additionally, increase
in the cytosolic Ca2+ concentration can also stimulate
mitochondrial ROS generation through various mechanisms8 Experimental Diabetes Research
[95]. Increased mitochondrial Ca2+ loading can generate
ROS as byproduct of the electron transport chain and can
mediate cytochrome c release and apoptosis [108]. Ca2+ may
also stimulate the Krebs cycle in endothelial cells thereby
increasingO2 consumptionandROSgeneration[109].Ca2+-
induced stimulation of eNOScanyield largeamountsof NO,
which can react with the superoxide anion to form ONOO−,
thereby oxidizing BH4 and promoting eNOS uncoupling
[106].
6.2. Hyperglycemia-Induced Endothelial Cell Apoptosis—Role
ofERStress. ERstressresponsetransducersinitiateapoptosis
once resolution of the stress has not been achieved. However,
the point at which the “apoptotic switch” is activated in
response to ER stress has not yet been elucidated. ER
responses to unfolded proteins (adaptation, alarm, and
apoptosis) are primarily mediated through IRE1 [59]. IRE1
activation leads to the activation of XBP1 (adaptation),
tumor necrosis factor receptor-associated factor 2 (TRAF2)
TRAF2 (alarm through NFκB), and JNK and p38MAPK
pathways (apoptosis through ASK1 and caspase-12) [59,
73]. High glucose exposure of endothelial cells and high
glucose-mediated oxidative stress in endothelial cells are
known to activate ASK1 [110, 111]. ASK1 can also cause
NO deﬁciency (a hallmark of endothelial cell dysfunction in
diabetes)byregulatingeNOS[112].Oxidantstress-mediated
ASK1 activation can cause downregulation of antiapoptotic
Bcl-2, disruption of the mitochondrial membrane potential,
and activation of a caspase cascade [113]. As mentioned
earlier CHOP/GADD153 activates apoptosis by downreg-
ulating Bcl-2 [81]. Bcl-2 is known to be reduced in high
glucose-exposed endothelial cells which may lead to the
increase in intracellular AGE (characteristic of endothelial
cell dysfunction in diabetes levels) [114, 115]. Linking the
modulation of ASK1 and Bcl-2 levels in hyperglycemia, ER
stress response might play a critical role in endothelial cell
dysfunction in diabetes.
It has been shown that high glucose induces apoptosis of
humanendothelialcellsthroughsequentialactivationofJNK
and caspase-3 [116]. Studies suggest that caspase-12, an ER
stress response mediator of apoptosis, can activate caspase-3
[73]. Blocking JNK and caspase-3 activity in high glucose-
exposed human endothelial cells in culture prevented high
glucose-induced apoptosis [116]. Additionally, vitamin C
treatment (antioxidant) reduced JNK levels in these high
glucose-exposed cells [116]. Given the role of ER stress
response in JNK caspase-12 activation, the high glucose-
induced ROS generation-mediated increase in endothelial
cell apoptosis due to the activation of JNK and caspase-3
activity and its reversal with blockade of JNK/caspases-3 or
antioxidant treatment indicate that ER stress might play a
signiﬁcant role in endothelial cell dysfunction in diabetes.
Tumor necrosis factor-α (TNFα), another known activa-
tor of the JNK pathway and inducer of apoptosis of endothe-
lial cells, is known to be activated by high glucose-induced
oxidative stress [117–120]. TNFα c a ni nt u r ng e n e r a t eR O S
and reduce activation of eNOS [121]. TNFα activation and
its binding to its receptor TNFR1 recruit TRAF2 leading to
downstream activation of NFκB, JNK and caspases which
in turn decides cell death and survival decisions [120].
Increase in the levels of TRAF2 has been shown in high
glucose-exposed endothelial cells [122]. TRAF2, known to
be essential for ER stress induced IRE1 mediated UPR, can
be an important link for the role of ER stress in endothelial
cell dysfunction in diabetes.
p58IPK inhibits PERK,therebyinhibiting eIF2α phospho-
rylation and returning ER homeostasis in stressed cells [84].
p58IPK transfection may have signiﬁcantly reduced apoptosis
of retinal endothelial cells by decreasing both mRNA and
protein levels of CHOP and TNFα in the retina of diabetic
rats, thereby reducing retinal blood vessel leakage [123,
124]. As in the case of pancreatic β-cells [85], prolonged
exposure of endothelial cells to high glucose levels might
decrease p58IPK leading to ER stress-mediated endothelial
cell dysfunction in diabetes.
6.3. Endothelial Cell Response to Insulin in Diabetes—Role
of ER Stress. Cellular insulin resistance may be selective in
terms of its nature and extent with respect to certain cell
systems and may vary in terms of the metabolic, mitogenic,
pro-survival, and vascular actions of insulin [16]. Protective
eﬀects of insulin include its ability to protect against
apoptosis and to stimulate the production of NO [125, 126].
The role of insulin resistance at the level of the endothelial
cell in vascular diseases is rather unclear.
The increase in the protein-folding demand and the
signaling involving calcium and ROS induce the UPR,
leading to the transcription of genes whose products mount
an inﬂammatory response. An excess of glucose can further
boost the UPR and inﬂammation, contributing to insulin
resistance and apoptosis. The ER stress response-conferred
insulin resistance in endothelial cells could also further
promote inﬂammatory stress signaling and contribute to
the metabolic deterioration that is associated with type II
diabetes and vascular diseases. JNK and IκB kinase (IKK) are
activated (through an IRE-1-alpha dependent fashion), in
addition to proinﬂammatory genes, in response to ER stress
in these cells as well [82, 127]. Activated JNK phosphorylates
serineresiduesonIRS-1,therebyinhibitingit,andtheoverall
insulin-signaling pathway. This in turn leads to insulin
resistance through defective downstream signaling (causing
less AKT activation and lower NO production) [82, 128].
7. Potential Therapeutic Strategies
Studies have brought to light the possible link between
hyperglycemia-induced ER stress and endothelial cell dys-
function. Given the relationship between oxidative stress and
ER stress, the probable ﬁrst line of therapy would be the
use of biologically known and pharmacologically available
antioxidants. Thioredoxin-1 (Trx1), an extensively studied
antioxidant, growth regulator, and antiapoptotic protein,
is known to interact with and inhibit ASK1 activity [27],
one of the prime mediators of ER stress-related apoptotic
response. Recently, it was reported that hyperglycemia-
induced oxidative stress was primarily due to the induction
ofTrx1inhibitoryprotein(TXNIP),anendogenousinhibitor
of Trx1 activity, leading to the inhibition of the antioxidantExperimental Diabetes Research 9
function of Trx1 [129]. TXNIP binding to Trx1 further
reduces the ability of Trx1 to bind eﬃciently with its
other protein partners, such as ASK-1 thereby reducing the
antiapoptotic property of Trx1 [129]. Studies are warranted
to investigate the role of Trx1 and TXNIP in the induction of
ER stress response to hyperglycemia in endothelial cells.
Preserving or restoring ER function might be therapeu-
tic.Certainsmallmolecules(chemicalchaperones)suchas4-
phenylbutyric acid and taurine-conjugated ursodeoxycholic
acid were found to signiﬁcantly reduce phosphorylation of
PERK and IRE1α to improve glucose tolerance and insulin
sensitivity [130]. A tetrameric form of resveratrol (vaticanol
B) exhibited the capacity to inhibit UPR and inﬂammatory
response by reducing protein-folding load and maintaining
membrane integrity thereby preventing ER stress-induced
apoptosis [131]. Salvianolic acid B was recently shown
to protect endothelial cells from oxidative stress damage
through the induction of GRP78 [100]. Salubrinal-induced
dephosphorylation of eIF2α has shown to protect cells from
ER stress-induced apoptosis [132].
ERAD involves the Ubiquitin-26S proteasome degrada-
tion pathway in the tagging and degradation of terminally
unfolded proteins. Eﬃciency of the ubiquitin-proteasome
system pathway in eliminating the unfolded proteins prob-
ably decides the fate of the cell [133]. A compromised
ERAD/ubiquitin-proteasome system would mean that even
though there has been a check on the synthesis of unfolded
proteins through ER stress response, the cell is unable to
get rid of accumulated misfolded proteins. This would mean
that since the ER stress cannot be resolved the cell has
to undergo apoptosis. Hyperglycemia is known to impair
proteasome function [134] .T h el o s so ff u n c t i o no ft h e
ubiquitin-proteasome system and continuing accumulation
of unfolded proteins in the ER might be the “apop-
totic switch” which when turned on demands the cell to
switch gears from prosurvival mode to proapoptotic mode.
Hence impaired ERAD/ubiquitin-proteasome system would
play a signiﬁcant role in hyperglycemia-induced ER stress
and endothelial cell dysfunction. Therapeutic strategies to
improvetheeﬃcacyoftheubiquitin-proteasomesystemthus
could possibly confer protection from diabetes-associated
endothelial cell dysfunction and oxidative stress.
8. Conclusion
Inconclusion,thecurrentpapersuggeststheroleofdiabetes-
mediated ER stress in the endothelial cell dysfunction and
accompanying cardiovascular diseases in diabetes. These
possible links between hyperglycemia-induced ER stress and
oxidative stress might oﬀer the premises for conducting
additional experiments to establish a uniﬁed molecular
mechanism and thereby identify a potential therapeutic
target in reducing vascular complications in diabetes. Eluci-
dation of this molecular mechanism could also extend this to
other pathological conditions where ER stress and oxidative
stress might play a causal role. Thus a direct response to
the current paper would be to test potential therapeutic
agents(antioxidantsand/orchemicalchaperones)thatmight
aid in long-term restoration of the endogenous capacity
of endothelial cells to initiate and ER stress response in
response to high glucose-induced protein misfolding, restore
ER homeostasis, and escape apoptosis.
More studies are required to establish a time-dependent
variation in the expression of ER stress proteins in a
diabetic milieu. It is possible that in early stages of diabetes
the endothelial cell may compensate for the ER stress
that is associated with hyperglycemia while in later stages
of advanced diabetes these compensatory mechanisms fail
resulting in endothelial cell dysfunction and associated
complications. Moreover, studies are required with adequate
glycemic controls to examine whether the extent or duration
of hyperglycemia could possibly regulate the expression of
ER stress transducers.
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